Q3 2024 Earnings Call Transcript November 3, 2024 Operator: Good day, and welcome to the Kymera Therapeutics Third Quarter ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $52.83, along ...

Kymera Therapeutics is pivoting focus from oncology to immunology, with plans to only develop cancer programs beyond phase 1 studies via partnerships. The Watertown, Massachusetts-based biotech is ...

WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using ...

About Kymera Therapeutics Kymera is a clinical-stage ... For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.

Kymera Therapeutics (NASDAQ:KYMR) is set to give its latest quarterly earnings report on Thursday, 2024-10-31. Here's what investors need to know before the announcement. Analysts estimate that ...

Kymera Therapeutics, Inc. (KYMR) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known ...

Oct. 31, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ ... For more information about our science, pipeline and people, please visit or follow us on X or LinkedIn ...

Ratings for Kymera Therapeutics (NASDAQ:KYMR) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise ...

Good day, and welcome to the Kymera Therapeutics Third Quarter 2024 Results ... both capital and people, are best focused on our expanding immunology pipeline. It should be noted that we did ...